advertisement
Bejanian M 9
Showing records 1 to 9 | Display all abstracts from Bejanian M78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Weinreb RN
Ophthalmology 2018; 125: 1874-1885
79202 Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
Seal JR; Robinson MR
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 50-57
78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Liebmann JM; Cioffi GA
Ophthalmology 2018; 125: 1874-1885
79202 Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
Burke J; Bejanian M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 50-57
78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Goldberg I
Ophthalmology 2018; 125: 1874-1885
79202 Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
Coote M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 50-57
78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Brandt JD; Johnson CA
Ophthalmology 2018; 125: 1874-1885
79202 Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
Attar M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 50-57
78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Zangwill LM; Schneider S; Badger H; Bejanian M
Ophthalmology 2018; 125: 1874-1885
